GENZ, PWRM, & SNY: Blink on Friday And Miss Massive Biotech Spikes

July 23, 2010 - PRLog -- Recent News: Blink on Friday And Miss Massive Biotech Spikes

Genzyme Corporation  announced that it has entered into an agreement with Goldman, Sachs & Co. to repurchase $1 billion of Genzyme common stock under an accelerated stock repurchase program. Proceeds from its recently concluded debt offering will be used to support this first tranche of Genzyme’s overall $2 billion share repurchase plan announced in May.

Genzyme Corporation is one of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

For more information visit: www.genzyme.com

__________________________________



POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)

PWRM is now available for $0.036 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover.

Continue your research at www.power3medical.com

__________________________________




SNY, Sanofi-Aventis

SNY, a pharmaceutical company, contributes to enhancing life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in the United States and Europe.

SNY and the Juvenile Diabetes Research Foundation (JDRF) reported a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease — both those living with the disease and the newly diagnosed — as well as preventing diabetes in those at risk.

Toward those goals, the partnership will focus on therapeutics such as immune therapies and beta cell regeneration.

Under the partnership, sanofi-aventis and JDRF will jointly provide academic investigators and non-profit medical research organizations with funding to conduct research projects in regeneration and immune therapy. This partnership will provide sanofi-aventis with options to the intellectual property developed by researchers who receive funding through the program.

More about SNY at en.sanofi-aventis.com



*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************




THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

*******************************************

# # #

Crown Equity Holdings Inc. assists and consults with domestic and foreign companies interested in becoming publicly traded in the U.S. The company designs and manufactures multi-monitor computer systems for financial traders and audio/video professionals.